Literature DB >> 3881939

Neoplasms of the immune system in rheumatoid arthritis.

D P Symmons.   

Abstract

Two studies are reported of patients with rheumatoid arthritis. The first was a retrospective-prospective-prospective study and comprised a cohort of 489 patients with rheumatoid arthritis followed for a mean of 12.2 years. Lymphoproliferative malignancies developed in 10 patients (2.2 percent) after a mean interval of 11.8 years. The second was a study of 30 patients, from various centers in England, with rheumatoid arthritis and lymphoproliferative malignancies. The effects of chronicity of rheumatoid arthritis, drug therapy, and possible predisposing factors in the etiology of the lymphoproliferative malignancies were examined. Cytotoxic drugs could not be implicated in the pathogenesis of the lymphoproliferative malignancies, but phenylbutazone and D-penicillamine may have played a role in some cases. Current evidence supports the hypothesis that chronic synovitis in rheumatoid arthritis is associated with persistent activation of lymphocytes in lymph nodes and eventual malignant transformation in some cases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3881939     DOI: 10.1016/0002-9343(85)90241-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  13 in total

1.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 2.  Multiple haematological malignancies in a patient with rheumatoid arthritis without exposure to disease modifying therapy.

Authors:  H Piper; D Mulherin; N Hardwick
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

3.  Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

Authors:  E Baecklund; A Ekbom; P Sparén; N Feltelius; L Klareskog
Journal:  BMJ       Date:  1998-07-18

4.  Evidence for oligoclonal B cell expansion in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D A Fox; B R Smith
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

Review 5.  Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.

Authors:  Meenakshi Bewtra; James D Lewis
Journal:  Expert Rev Clin Immunol       Date:  2010-07       Impact factor: 4.473

Review 6.  Lymphoma in patients with rheumatoid arthritis: what is the evidence of a link with methotrexate?

Authors:  L Georgescu; S A Paget
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 7.  What happens to patients with rheumatoid arthritis? The long-term outcome of treatment.

Authors:  T D Spector; D L Scott
Journal:  Clin Rheumatol       Date:  1988-09       Impact factor: 2.980

8.  Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.

Authors:  J Askling; C M Fored; E Baecklund; L Brandt; C Backlin; A Ekbom; C Sundström; L Bertilsson; L Cöster; P Geborek; L T Jacobsson; S Lindblad; J Lysholm; S Rantapää-Dahlqvist; T Saxne; L Klareskog; N Feltelius
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

9.  Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis.

Authors:  Jing-Xian Xu; Yoshihiko Hoshida; Tadashi Hongyo; Toru Sasaki; Hajime Miyazato; Yasuhiko Tomita; Katsuyuki Aozasa
Journal:  J Cancer Res Clin Oncol       Date:  2006-09-20       Impact factor: 4.553

10.  The risk of leukemia in patients with rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Xiao Luo; Yue He; Wangdong Xu; Mao Liu; Zixia Zhao; Lihui Peng; Chengsong He; Jie Chen
Journal:  Clin Rheumatol       Date:  2020-09-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.